These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Yokota T; Milenic DE; Whitlow M; Wood JF; Hubert SL; Schlom J Cancer Res; 1993 Aug; 53(16):3776-83. PubMed ID: 8339291 [TBL] [Abstract][Full Text] [Related]
3. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Nielsen UB; Adams GP; Weiner LM; Marks JD Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810 [TBL] [Abstract][Full Text] [Related]
4. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting. Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757 [TBL] [Abstract][Full Text] [Related]
5. Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: potential advantages over antibodies expressed within the intracellular environment (Intrabody). Heng BC; Cao T Med Hypotheses; 2005; 64(6):1105-8. PubMed ID: 15823695 [TBL] [Abstract][Full Text] [Related]
6. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795 [TBL] [Abstract][Full Text] [Related]
7. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs. Wittel UA; Jain M; Goel A; Chauhan SC; Colcher D; Batra SK Nucl Med Biol; 2005 Feb; 32(2):157-64. PubMed ID: 15721761 [TBL] [Abstract][Full Text] [Related]
11. Medical applications of single-chain antibodies. Huston JS; McCartney J; Tai MS; Mottola-Hartshorn C; Jin D; Warren F; Keck P; Oppermann H Int Rev Immunol; 1993; 10(2-3):195-217. PubMed ID: 8360586 [TBL] [Abstract][Full Text] [Related]
12. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies. Wang X; Campoli M; Ko E; Luo W; Ferrone S J Immunol Methods; 2004 Nov; 294(1-2):23-35. PubMed ID: 15604013 [TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct. Pavlinkova G; Booth BJ; Batra SK; Colcher D Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640 [TBL] [Abstract][Full Text] [Related]
14. Single-chain antibodies in pancreatic cancer. Colcher D; Pavlinkova G; Beresford G; Booth BJ; Batra SK Ann N Y Acad Sci; 1999 Jun; 880():263-80. PubMed ID: 10415872 [TBL] [Abstract][Full Text] [Related]
15. Anti-estradiol-17beta single-chain Fv fragments: Generation, characterization, gene randomization, and optimized phage display. Kobayashi N; Kato Y; Oyama H; Taga S; Niwa T; Sun P; Ohtoyo M; Goto J Steroids; 2008 Dec; 73(14):1485-99. PubMed ID: 18824188 [TBL] [Abstract][Full Text] [Related]
16. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility. Albrecht H; Denardo GL; Denardo SJ J Immunol Methods; 2006 Mar; 310(1-2):100-16. PubMed ID: 16499921 [TBL] [Abstract][Full Text] [Related]
17. In vivo targeting of malignant melanoma by 125Iodine- and 99mTechnetium-labeled single-chain Fv fragments against high molecular weight melanoma-associated antigen. Kang N; Hamilton S; Odili J; Wilson G; Kupsch J Clin Cancer Res; 2000 Dec; 6(12):4921-31. PubMed ID: 11156253 [TBL] [Abstract][Full Text] [Related]
18. Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen. Bejcek BE; Wang D; Berven E; Pennell CA; Peiper SC; Poppema S; Uckun FM; Kersey JH Cancer Res; 1995 Jun; 55(11):2346-51. PubMed ID: 7538901 [TBL] [Abstract][Full Text] [Related]
19. Effects of genetic engineering on the pharmacokinetics of antibodies. Colcher D; Goel A; Pavlinkova G; Beresford G; Booth B; Batra SK Q J Nucl Med; 1999 Jun; 43(2):132-9. PubMed ID: 10429508 [TBL] [Abstract][Full Text] [Related]
20. Gene cloning, bacterial expression, in vitro refolding, and characterization of a single-chain Fv antibody against PreS1(21-47) fragment of HBsAg. Yang X; Hu W; Li F; Xia H; Zhang Z Protein Expr Purif; 2005 Jun; 41(2):341-8. PubMed ID: 15866720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]